Hukuoka, Japan
- Featured
Study to evaluate HZN-825 in patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial for HZN-825, a selective antagonist of lysophosphatidic acid receptor-1 (LPAR1). Participants will be screened within 4 weeks prior to the Baseline (Day 1) Visit. Approximately 300 participants who meet the trial eligibility criteria will be randomized on Day 1 in a 1:1:1 ratio to receive HZN-825 300 mg QD, HZN-825 300 mg BID or placebo for 52 weeks. Participants will take their first dose of trial drug at the clinic and will return to the clinic for trial visits at Week 4 and every 6 weeks thereafter until Week 52. Participants who complete the Double-blind Treatment Period (Week 52) may be eligible to enter a 52-week extension trial (HZNP- HZN-825-302). Participants not entering the extension will return to the clinic for a Safety Follow-up Visit 4 weeks after the last dose of trial drug.
Phase
2Span
139 weeksSponsor
Horizon Therapeutics Ireland DACFukuoka
Recruiting
- Featured
Fukuoka-Shi
Recruiting
- Featured
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Phase
1Span
194 weeksSponsor
Incyte CorporationFukuoka
Recruiting
- Featured
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)
For more information, please contact Incyte Corporation at 1.855.463.3463 or visit **[www.incyteclinicaltrials.com](https://www.incyteclinicaltrials.com/)**
Phase
3Span
Sponsor
Fukuoka-Shi
Recruiting
A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial Cystitis
Phase
2Span
79 weeksSponsor
Ono Pharmaceutical Co. LtdFukuoka
Recruiting
A Clinical Study of ONO-1110 in Patients With Fibromyalgia
Phase
2Span
83 weeksSponsor
Ono Pharmaceutical Co. LtdFukuoka
Recruiting
A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan
Phase
2/3Span
48 weeksSponsor
TakedaFukuoka
Recruiting
Healthy Volunteers
Nipocalimab in Moderate to Severe Sjogren's Disease
This clinical development program for nipocalimab in SjD includes 2 identical double blind, placebo-controlled studies to evaluate the efficacy, safety, and tolerability of nipocalimab in participants greater than or equal to (>=) 18 years of age with moderate to severe SjD.
Phase
3Span
286 weeksSponsor
Janssen Research & Development, LLCFukuoka
Recruiting
ONO-4059 Study in Patients With Steroid-resistant Pemphigus
Phase
3Span
346 weeksSponsor
Ono Pharmaceutical Co. LtdFukuoka
Recruiting
A Study of LY4065967 in Healthy Japanese Participants
Phase
1Span
23 weeksSponsor
Eli Lilly and CompanyFukuoka
Recruiting
Healthy Volunteers